EAT thickness
1 paper1 finding
- Human trial1
Interventions
1Dapagliflozin
downin humans1
1 study
Dapagliflozin
downin humans1
Dapagliflozin decreases EAT thickness in humans (median change -0.8 mm vs. 0.1 mm).
“Dapagliflozin significantly reduced average EAT thickness compared with placebo (median change -0.8 mm [interquartile range (IQR): -1.3 to -0.4] vs. 0.1 mm [IQR: -0.1 to 0.3]).”
Human trialtype 2 diabetes mellitus10 mg daily12 months
Journal of magnetic resonance imaging : JMRI26 Aug 2026
Latest
2 in 12 monthsIrish Journal of Medical Science
Association of pericoronary and epicardial adipose tissue thickness with coronary artery calcium score using cardiac computed tomography
Cross-sectional study of 1,032 peopleCoronary artery calcium score
Journal of Magnetic Resonance Imaging
Impact of Dapagliflozin on MRI-Derived Epicardial Adipose Tissue: Secondary Imaging Analysis of a Randomized Trial
Randomised trial in 56 peopleDapagliflozin
Nutrition, Metabolism, and Cardiovascular Diseases
Very low-calorie ketogenic diet reduces left ventricular mass and epicardial adipose tissue in post-menopausal women with essential hypertension and obesity: A single-center, prospective, open-label, clinical study
Non-randomised trial in 43 peopleKetogenic diet
ADA Scientific Sessions 2025 Abstract
The Significant Reduction in Epicardial Adipose Tissue Thickness after Dapagliflozin Treatment Is Preserved and Even Increased after Four Years—The DAPAHEART Four-Year Follow-up Study
Randomised trial in peopleDapagliflozin